PDE5抑制剂与cGMP信号通路相关疾病的研究进展  

Advances in PDE5 inhibitors and diseases related to cGMP signaling pathway

作　　者：郭文钧 高冉[1] 樊天斐 王婧[1] GUO Wen-jun;GAO Ran;FAN Tian-fei;WANG Jing(Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences,School of Basic Medicine,Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院基础医学研究所,北京协和医学院基础学院,北京100730

出　　处：《中国病理生理杂志》2021年第1期159-165,共7页Chinese Journal of Pathophysiology

基　　金：国家自然科学基金资助项目(No.81622008,No.91739107)。

摘　　要：磷酸二酯酶5(phosphodiesterase 5,PDE5)抑制剂通过阻断环磷酸鸟苷(cyclic guanosine monophosphate,cGMP)的分解,使包括一氧化氮(nitric oxide,NO)在内的血管舒张介质作用延长,从而导致阴茎和肺的血管舒张。PDE5主要在阴茎海绵体和肺血管中发现,所以其抑制剂的主要作用是延长阴茎勃起和降低肺血管压力。Phosphodiesterase 5(PDE5)inhibitors,as drugs to dilate the corpora cavernosa of the penis through sexual stimulation,are used to treat erectile dysfunction,and are also approved for treating pulmonary arterial hypertension.With the in-depth studies,PDE5 inhibitors have been approved to treat a variety of diseases,such as cardiovascular diseases,Alzheimer disease,etc,but there is currently no overall review on clinical applications of PDE5 inhibitors.As known,the classic pathway of PDE5 inhibitors promotes cyclic guanosine monophosphate(cGMP)production.However,reports on downstream pathways regulated by cGMP are still unclear.This review summarized the research and clinical application progress of PDE5 inhibitors in different diseases,and the pharmacological bases of PDE5 inhibitors through cGMP signaling pathway are discussed.

关 键 词：磷酸二酯酶5 抑制剂 西地那非 环磷酸鸟苷 

分 类 号：R363[医药卫生—病理学] R983[医药卫生—基础医学]